Company
CRISPR Therapeutics
CRISPR Therapeutics has 10 drugs tracked on RxWires: 4 in Phase 1/2, 6 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| CTX460 | Phase 1/2 | Alpha-1 Antitrypsin Deficiency (AATD) |
| CTX112 | Phase 1/2 | B-cell Lymphoma |
| CTX340 | Phase 1/2 | Hypertension |
| CTX110 | Phase 1/2 | B-cell Malignancy |
| VCTX210A unit | Phase 1 | Diabetes Mellitus |
| CTX120 | Phase 1 | Multiple Myeloma |
| CTX131 | Phase 1 | Clear Cell Renal Cell Carcinoma |
| CTX310 | Phase 1 | Cardiovascular |
| CTX130 | Phase 1 | T Cell Lymphoma |
| VCTX211 | Phase 1 | Diabetes Mellitus |
Latest
- crispr therapeutics filed 8-K
- crispr therapeutics filed 8-K
- crispr therapeutics filed 8-K
- crispr therapeutics filed 8-K
- crispr therapeutics filed 8-K
Follow CRISPR Therapeutics on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.